Pliant Therapeutics (PLRX) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pliant Therapeutics (PLRX) has outperformed Spero Therapeutics (SPRO) over the past year, losing 34.6% versus a loss of 50.0%. Over five years, SPRO leads with a -93.3% price change compared with -94.4% for PLRX. Spero Therapeutics is the larger company by market cap ($69.9 million vs $63.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLRX | SPRO |
|---|---|---|
| Share price | $1.02 | $1.20 |
| Market cap | $63.16M | $69.88M |
| 1-day change | +2.00% | +5.26% |
| YTD return | -18.03% | -51.07% |
| 1-year return | -34.64% | -50.00% |
| 5-year return | -94.44% | -93.30% |
| P/E ratio (TTM) | — | 8.57 |
| EPS (TTM) | $-1.50 | $0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.95 | $3.08 |
| 52-week low | $0.97 | $1.08 |
| Distance from 52-week high | -47.69% | -61.04% |
| Analyst consensus | none | none |
| Avg. price target upside | +96.08% | +316.67% |
| Average volume | 477.96K | 1.20M |
| Shares outstanding | 61.92M | 58.23M |
| Employees | 49 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRX has outperformed SPRO by 15.4 percentage points over the past year.
About Pliant Therapeutics
PLRX stock →Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
PLRX vs SPRO FAQ
Which is bigger, Pliant Therapeutics or Spero Therapeutics?
Spero Therapeutics (SPRO) is larger, with a market capitalization of $69.88M compared with $63.16M for Pliant Therapeutics (PLRX).
Which stock has performed better over the past year, PLRX or SPRO?
PLRX returned -34.64% over the past 12 months, compared with -50.00% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are Pliant Therapeutics and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.